Bibliographic Details
| Title: |
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial |
| Authors: |
Ruan, Dan-Yun a, †, Liu, Fu-Rong a, †, Wei, Xiao-Li b, †, Luo, Su-Xia c, Zhuang, Zhi-Xiang d, Wang, Zhen-Ning e, Liu, Fu-Nan e, Zhang, Yan-Qiao f, Yang, Jian-Wei g, Chen, Zhen-Dong h, Wang, Yong-Sheng i, Wang, Jun-Ye j, Liang, Xiao-Hua k, Wu, Xiao-Jie l, Zheng, Yu-Long m, Liu, Jian n, Shi, Xi o, Kumar, Rakesh p, Liu, Wei q, Chen, Bo q, Zhang, Dong-Sheng b, **, Xu, Rui-Hua b, * |
| Source: |
In The Lancet Oncology February 2025 26(2):227-238 |
| Database: |
ScienceDirect |
